ACTB and non-small cell lung carcinoma: A somewhat different result was reported in rat injured spinal tissues treated with CXB plus fasudil (a rho-associated kinase inhibitor) [77] and in human non-small cell lung cancer treated with CXB plus aspirin [78], where the content of β-actin [77] and α-tubulin [78] was not affected by the drug combination.